ArticleJournal of hepatology2021
Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.
Luke Boulter, Mo R Ebrahimkhani
Abstract readEditorialComment
In one paragraphArticle in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
2 authors.
Luke BoulterMRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK. Electronic address: Luke.Boulter@ed.ac.uk.
Mo R EbrahimkhaniDepartment of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA, USA; Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, USA; McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: mo.ebr@pitt.edu.
Funding
Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Gavin E Arteel · 2019 to 2026
$10.9MRecreating Human Developmental Hematopoietic Niches for Ex Vivo Biomanufacturing of Blood Stem CellsR01HL141805 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mo Reza Ebrahimkhani · 2019 to 2026
$2.6MIntegration of systems and synthetic biology to advance development of human tissues ex vivoR01EB028532 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI EBRAHIMKHANI, MO REZA · 2019 to 2022
$1.7MCancer Research UK 27948Cancer Research UK C52499/A27948NHLBI NIH HHS R01 HL141805NIBIB NIH HHS R01 EB028532NIDDK NIH HHS P30 DK120531
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Biliary TractOrganoidsCarcinogenesisCell Transformation, NeoplasticHumansReceptor, Fibroblast Growth Factor, Type 2FGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2biliarycancerFGFR2 fusion proteinsliverOrganoidsstem cells
Identifiers
PMID34029636
PMCPMC8887813
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390